Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 210
Filter
1.
Front Endocrinol (Lausanne) ; 14: 1161356, 2023.
Article in English | MEDLINE | ID: mdl-38075074

ABSTRACT

Background: Testosterone plays a key role in women, but the associations of serum testosterone level with gynecological disorders risk are inconclusive in observational studies. Methods: We leveraged public genome-wide association studies to analyze the effects of four testosterone related exposure factors on nine gynecological diseases. Causal estimates were calculated by inverse variance-weighted (IVW), MR-Egger and weighted median methods. The heterogeneity test was performed on the obtained data through Cochrane's Q value, and the horizontal pleiotropy test was performed on the data through MR-Egger intercept and MR-PRESSO methods. "mRnd" online analysis tool was used to evaluate the statistical power of MR estimates. Results: The results showed that total testosterone and bioavailable testosterone were protective factors for ovarian cancer (odds ratio (OR) = 0.885, P = 0.012; OR = 0.871, P = 0.005) and endometriosis (OR = 0.805, P = 0.020; OR = 0.842, P = 0.028) but were risk factors for endometrial cancer (OR = 1.549, P < 0.001; OR = 1.499, P < 0.001) and polycystic ovary syndrome (PCOS) (OR = 1.606, P = 0.019; OR = 1.637, P = 0.017). dehydroepiandrosterone sulfate (DHEAS) is a protective factor against endometriosis (OR = 0.840, P = 0.016) and premature ovarian failure (POF) (OR = 0.461, P = 0.046) and a risk factor for endometrial cancer (OR= 1.788, P < 0.001) and PCOS (OR= 1.970, P = 0.014). sex hormone-binding globulin (SHBG) is a protective factor against endometrial cancer (OR = 0.823, P < 0.001) and PCOS (OR = 0.715, P = 0.031). Conclusion: Our analysis suggested causal associations between serum testosterone level and ovarian cancer, endometrial cancer, endometriosis, PCOS, POF.


Subject(s)
Genital Diseases, Female , Menopause, Premature , Ovarian Neoplasms , Polycystic Ovary Syndrome , Primary Ovarian Insufficiency , Female , Humans , Endometrial Neoplasms/genetics , Endometriosis/genetics , Genital Diseases, Female/genetics , Genome-Wide Association Study , Mendelian Randomization Analysis , Ovarian Neoplasms/etiology , Ovarian Neoplasms/genetics , Polycystic Ovary Syndrome/genetics , Primary Ovarian Insufficiency/genetics , Testosterone/blood , Testosterone/genetics
2.
J Med Life ; 16(9): 1343-1349, 2023 Sep.
Article in English | MEDLINE | ID: mdl-38107722

ABSTRACT

Male hypogonadism and erectile dysfunction in different populations are associated with excess body weight. A key aspect in most studies is the metabolism of sexual hormones, primarily testosterone. At the same time, the binding protein sex hormone binding globulin (SHBG) can play a large role, as it determines the ratio of total and bioavailable testosterone in blood, i.e. both the hormone content and level of its production. Recent research has identified common mutations that affect SHBG levels, such as the rs727428 polymorphic locus, which is associated with alterations in histone protein function, affecting the regulation of ribonucleic acid (RNA) protein SHBG synthesis. Similar relationships have been observed for prevalent mutations, including rs5934505 and rs10822184, in diverse populations. This study involved 300 individuals of Kazakh nationality from the Eastern Kazakhstan region, examining three polymorphic variants of the SHBG gene (rs727428, rs5934505, and rs10822184). The participants were categorized into three groups: individuals with hypogonadism and obesity (group 1, n=85), those with excess body weight but no hypogonadism (group 2, n=70), and individuals with neither excess body weight nor hypogonadism (group 3, n=145). The frequency of mutant gene alleles impacting GPS (SHBG) synthesis in the Kazakh population was notably high, comparable to European and South-East Asian populations. However, the association between excess body weight and these mutations exhibited varying patterns. Hypogonadism was linked to decreased GPS levels, strongly correlating with total testosterone but not bioavailable testosterone. The retention of sexual functions in overweight men was not always directly related to BMI levels and GPS concentrations.


Subject(s)
Erectile Dysfunction , Hypogonadism , Male , Humans , Overweight/genetics , Hypogonadism/genetics , Hypogonadism/epidemiology , Testosterone/genetics , Obesity/genetics
3.
Front Endocrinol (Lausanne) ; 14: 1239502, 2023.
Article in English | MEDLINE | ID: mdl-37916150

ABSTRACT

Background: Aging is an inescapable process, but it can be slowed down, particularly facial aging. Sex and growth hormones have been shown to play an important role in the process of facial aging. We investigated this association further, using a two-sample Mendelian randomization study. Methods: We analyzed genome-wide association study (GWAS) data from the UK Biobank database comprising facial aging data from 432,999 samples, using two-sample Mendelian randomization. In addition, single-nucleotide polymorphism (SNP) data on sex hormone-binding globulin (SHBG) and sex steroid hormones were obtained from a GWAS in the UK Biobank [SHBG, N = 189,473; total testosterone (TT), N = 230,454; bioavailable testosterone (BT), N = 188,507; and estradiol (E2), N = 2,607)]. The inverse-variance weighted (IVW) method was the major algorithm used in this study, and random-effects models were used in cases of heterogeneity. To avoid errors caused by a single algorithm, we selected MR-Egger, weighted median, and weighted mode as supplementary algorithms. Horizontal pleiotropy was detected based on the intercept in the MR-Egger regression. The leave-one-out method was used for sensitivity analysis. Results: SHBG plays a promoting role, whereas sex steroid hormones (TT, BT, and E2) play an inhibitory role in facial aging. Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels had no significant effect on facial aging, which is inconsistent with previous findings in vitro. Conclusion: Regulating the levels of SHBG, BT, TT, and E2 may be an important means to delay facial aging.


Subject(s)
Biological Specimen Banks , Genome-Wide Association Study , Growth Hormone , Testosterone , Growth Hormone/genetics , Mendelian Randomization Analysis , Testosterone/genetics , United Kingdom/epidemiology
4.
Int J Epidemiol ; 51(6): 1931-1942, 2022 12 13.
Article in English | MEDLINE | ID: mdl-35218343

ABSTRACT

BACKGROUND: Sex hormone-binding globulin (SHBG), testosterone and oestradiol have been associated with many diseases in observational studies; however, the causality of associations remains unestablished. METHODS: A phenome-wide Mendelian randomization (MR) association study was performed to explore disease outcomes associated with genetically proxied circulating SHBG, testosterone and oestradiol levels by using updated genetic instruments in 339 197 unrelated White British individuals (54% female) in the UK Biobank. Two-sample MR analyses with data from large genetic studies were conducted to replicate identified associations in phenome-wide MR analyses. Multivariable MR analyses were performed to investigate mediation effects of hormone-related biomarkers in observed associations with diseases. RESULTS: Phenome-wide MR analyses examined associations of genetically predicted SHBG, testosterone and oestradiol levels with 1211 disease outcomes, and identified 28 and 13 distinct phenotypes associated with genetically predicted SHBG and testosterone, respectively; 22 out of 28 associations for SHBG and 10 out of 13 associations for testosterone were replicated in two-sample MR analyses. Higher genetically predicted SHBG levels were associated with a reduced risk of hypertension, type 2 diabetes, diabetic complications, coronary atherosclerotic outcomes, gout and benign and malignant neoplasm of uterus, but an increased risk of varicose veins and fracture (mainly in females). Higher genetically predicted testosterone levels were associated with a lower risk of type 2 diabetes, coronary atherosclerotic outcomes, gout and coeliac disease mainly in males, but an increased risk of cholelithiasis in females. CONCLUSIONS: These findings suggest that sex hormones may causally affect risk of several health outcomes.


Subject(s)
Estradiol , Sex Hormone-Binding Globulin , Testosterone , Female , Humans , Male , Estradiol/blood , Estradiol/genetics , Gonadal Steroid Hormones , Mendelian Randomization Analysis , Sex Hormone-Binding Globulin/genetics , Testosterone/blood , Testosterone/genetics
5.
Int J Mol Sci ; 22(22)2021 Nov 09.
Article in English | MEDLINE | ID: mdl-34829994

ABSTRACT

A sufficient vascular network within the feto-maternal interface is necessary for placental function. Several pregnancy abnormalities have been associated with abnormal vascular formations in the placenta. We hypothesized that growth and expansion of the placental vascular network in the equine (Equus caballus) placenta is regulated by estrogens (estrogen family hormones), a hormone with a high circulating concentration during equine gestation. Administration of letrozole, a potent and specific inhibitor of aromatase, during the first trimester (D30 to D118), decreased circulatory estrone sulfate concentrations, increased circulatory testosterone and androstenedione concentrations, and tended to reduce the weight of the fetus (p < 0.1). Moreover, the gene expression of CYP17A1 was increased, and the expression of androgen receptor was decreased in the D120 chorioallantois (CA) of letrozole-treated mares in comparison to that of the control mares. We also found that at D120, the number of vessels tended to decrease in the CAs with letrozole treatment (p = 0.07). In addition, expression of a subset of angiogenic genes, such as ANGPT1, VEGF, and NOS2, were altered in the CAs of letrozole-treated mares. We further demonstrated that 17ß-estradiol increases the expression of ANGPT1 and VEGF and increases the angiogenic activity of equine endothelial cells in vitro. Our results from the estrogen-suppressed group demonstrated an impaired placental vascular network, suggesting an estrogen-dependent vasculogenesis in the equine CA during the first trimester.


Subject(s)
Estrogens/genetics , Horses/genetics , Letrozole/pharmacology , Neovascularization, Physiologic/genetics , Androstenedione/genetics , Angiopoietin-1/genetics , Animals , Aromatase/genetics , Female , Gene Expression Regulation, Developmental/drug effects , Horses/growth & development , Maternal-Fetal Relations/drug effects , Neovascularization, Physiologic/drug effects , Placenta/blood supply , Placenta/drug effects , Pregnancy , Pregnancy Trimester, First , Receptors, Androgen/genetics , Steroid 17-alpha-Hydroxylase/genetics , Testosterone/genetics , Vascular Endothelial Growth Factor A/genetics
6.
Sci Rep ; 11(1): 14039, 2021 07 07.
Article in English | MEDLINE | ID: mdl-34234209

ABSTRACT

Life expectancy in the developed West is currently stagnated and remains shorter in men than women. Well-established evolutionary biology theory suggests lifespan trades-off against reproductive success, possibly sex-specifically. We examined whether a key driver of reproductive success, testosterone, affected survival using a Mendelian randomization longevity study in the UK Biobank to obtain unbiased estimates, along with control exposures. We applied published genetic instruments for testosterone to obtain inverse variance weighted estimates of associations with survival to (i.e., age at) recruitment, in 167,020 men and 194,174 women. We similarly obtained estimates for a positive control (smoking initiation), and a negative control (absorbate), a marker of vitamin C metabolism. Testosterone was associated with poorer survival (0.10 years younger at recruitment per effect size of testosterone, 95% confidence interval (CI) 0.004 to 0.20). As expected, smoking initiation was also associated with poorer survival (0.37 years younger, 95% CI 0.25 to 0.50), but not absorbate (0.01 years younger, 95% CI - 0.09 to 0.11). Several aspects of a healthy lifestyle (low animal fat diet) and several widely used medications (statins, metformin, dexamethasone and possibly aspirin) may modulate testosterone. Explicitly designing interventions sex-specifically based on these insights might help address stagnating life expectancy and sexual disparities.


Subject(s)
Life Expectancy , Longevity , Testosterone/metabolism , Biological Specimen Banks , Female , Healthy Lifestyle , Humans , Male , Mendelian Randomization Analysis , Population Surveillance , Risk Factors , Sex Factors , Testosterone/genetics , United Kingdom/epidemiology
7.
PLoS One ; 16(4): e0250454, 2021.
Article in English | MEDLINE | ID: mdl-33914781

ABSTRACT

In the epididymis, lysosomal proteins of the epithelial cells are normally targeted from the Golgi apparatus to lysosomes for degradation, although their secretion into the epididymal lumen has been documented and associated with sperm maturation. In this study, cathepsin D (CatD) and prosaposin (PSAP) were examined in adult epididymis of control, and 2-day castrated rats without (Ct) and with testosterone replacement (Ct+T) to evaluate their expression and regulation within epididymal epithelial cells. By light microscope-immunocytochemistry, a quantitative increase in size of lysosomes in principal cells of Ct animals was noted from the distal initial segment to the proximal cauda. Androgen replacement did not restore the size of lysosomes to control levels. Western blot analysis revealed a significant increase in CatD expression in the epididymis of Ct animals, which suggested an upregulation of its expression in principal cells; androgens restored levels of CatD to that of controls. In contrast, PSAP expression in Ct animals was not altered from controls. Additionally, an increase in procathepsin D levels was noted from samples of the epididymal fluid of Ct compared to control animals, accompanied by an increased complex formation with PSAP. Moreover, an increased oligomerization of prosaposin was observed in the epididymal lumen of Ct rats, with changes reverted to controls in Ct+T animals. Taken together these data suggest castration causes an increased uptake of substrates that are acted upon by CatD in lysosomes of principal cells and in the lumen by procathepsin D. These substrates may be derived from apoptotic cells noted in the lumen of proximal regions and possibly by degenerating sperm in distal regions of the epididymis of Ct animals. Exploring the mechanisms by which lysosomal enzymes are synthesized and secreted by the epididymis may help resolve some of the issues originating from epididymal dysfunctions with relevance to sperm maturation.


Subject(s)
Androgens/genetics , Cathepsin D/genetics , Enzyme Precursors/genetics , Saposins/genetics , Androgens/metabolism , Animals , Castration/adverse effects , Epididymis/growth & development , Epididymis/metabolism , Epithelial Cells/metabolism , Gene Expression Regulation/genetics , Lysosomes/genetics , Lysosomes/physiology , Male , Rats , Spermatozoa/metabolism , Testosterone/genetics , Testosterone/metabolism
9.
J Natl Cancer Inst ; 113(2): 192-198, 2021 02 01.
Article in English | MEDLINE | ID: mdl-33527137

ABSTRACT

BACKGROUND: Metformin has been associated with lower breast cancer (BC) risk and improved outcomes in observational studies. Multiple biologic mechanisms have been proposed, including a recent report of altered sex hormones. We evaluated the effect of metformin on sex hormones in MA.32, a phase III trial of nondiabetic BC subjects who were randomly assigned to metformin or placebo. METHODS: We studied the subgroup of postmenopausal hormone receptor-negative BC subjects not receiving endocrine treatment who provided fasting blood at baseline and at 6 months after being randomly assigned. Sex hormone-binding globulin, bioavailable testosterone, and estradiol levels were assayed using electrochemiluminescence immunoassay. Change from baseline to 6 months between study arms was compared using Wilcoxon sum rank tests and regression models. RESULTS: 312 women were eligible (141 metformin vs 171 placebo); the majority of subjects in each arm had T1/2, N0, HER2-negative BC and had received (neo)adjuvant chemotherapy. Mean age was 58.1 (SD=6.9) vs 57.5 (SD=7.9) years, mean body mass index (BMI) was 27.3 (SD=5.5) vs 28.9 (SD=6.4) kg/m2 for metformin vs placebo, respectively. Median estradiol decreased between baseline and 6 months on metformin vs placebo (-5.7 vs 0 pmol/L; P < .001) in univariable analysis and after controlling for baseline BMI and BMI change (P < .001). There was no change in sex hormone-binding globulin or bioavailable testosterone. CONCLUSION: Metformin lowered estradiol levels, independent of BMI. This observation suggests a new metformin effect that has potential relevance to estrogen sensitive cancers.


Subject(s)
Breast Neoplasms/drug therapy , Gonadal Steroid Hormones/antagonists & inhibitors , Metformin/administration & dosage , Body Mass Index , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Estradiol/genetics , Female , Gonadal Steroid Hormones/genetics , Humans , Middle Aged , Receptor, ErbB-2/genetics , Testosterone/antagonists & inhibitors , Testosterone/genetics
10.
Differentiation ; 118: 41-71, 2021.
Article in English | MEDLINE | ID: mdl-33441255

ABSTRACT

Estrogen has always been considered the female hormone and testosterone the male hormone. However, estrogen's presence in the testis and deleterious effects of estrogen treatment during development have been known for nearly 90 years, long before estrogen receptors (ESRs) were discovered. Eventually it was learned that testes actually synthesize high levels of estradiol (E2) and sequester high concentrations in the reproductive tract lumen, which seems contradictory to the overwhelming number of studies showing reproductive pathology following exogenous estrogen exposures. For too long, the developmental pathology of estrogen has dominated our thinking, even resulting in the "estrogen hypothesis" as related to the testicular dysgenesis syndrome. However, these early studies and the development of an Esr1 knockout mouse led to a deluge of research into estrogen's potential role in and disruption of development and function of the male reproductive system. What is new is that estrogen action in the male cannot be divorced from that of androgen. This paper presents what is known about components of the estrogen pathway, including its synthesis and target receptors, and the need to achieve a balance between androgen- and estrogen-action in male reproductive tract differentiation and adult functions. The review focuses on what is known regarding development of the male reproductive tract, from the rete testis to the vas deferens, and examines the expression of estrogen receptors and presence of aromatase in the male reproductive system, traces the evidence provided by estrogen-associated knockout and transgenic animal models and discusses the effects of fetal and postnatal exposures to estrogens. Hopefully, there will be enough here to stimulate discussions and new investigations of the androgen:estrogen balance that seems to be essential for development of the male reproductive tract.


Subject(s)
Androgens/metabolism , Estrogen Receptor alpha/genetics , Estrogens/metabolism , Testosterone/metabolism , Androgens/genetics , Animals , Embryo, Mammalian , Embryonic Development/genetics , Epididymis/growth & development , Epididymis/metabolism , Estradiol/metabolism , Estrogens/genetics , Female , Genitalia, Male , Male , Mice , Mice, Knockout/genetics , Rete Testis/growth & development , Rete Testis/metabolism , Testosterone/genetics
11.
Eur J Hum Genet ; 29(1): 154-163, 2021 01.
Article in English | MEDLINE | ID: mdl-32873964

ABSTRACT

Sex differences have been shown in laboratory biomarkers; however, the extent to which this is due to genetics is unknown. In this study, we infer sex-specific genetic parameters (heritability and genetic correlation) across 33 quantitative biomarker traits in 181,064 females and 156,135 males from the UK Biobank study. We apply a Bayesian Mixture Model, Sex Effects Mixture Model (SEMM), to Genome-wide Association Study summary statistics in order to (1) estimate the contributions of sex to the genetic variance of these biomarkers and (2) identify variants whose statistical association with these traits is sex-specific. We find that the genetics of most biomarker traits are shared between males and females, with the notable exception of testosterone, where we identify 119 female and 445 male-specific variants. These include protein-altering variants in steroid hormone production genes (POR, UGT2B7). Using the sex-specific variants as genetic instruments for Mendelian randomization, we find evidence for causal links between testosterone levels and height, body mass index, waist and hip circumference, and type 2 diabetes. We also show that sex-specific polygenic risk score models for testosterone outperform a combined model. Overall, these results demonstrate that while sex has a limited role in the genetics of most biomarker traits, sex plays an important role in testosterone genetics.


Subject(s)
Biomarkers/analysis , Multifactorial Inheritance/genetics , Sex Characteristics , Body Composition , Cytochrome P-450 Enzyme System/genetics , Female , Glucuronosyltransferase/genetics , Humans , Male , Mendelian Randomization Analysis , Testosterone/genetics
13.
Science ; 370(6513): 208-214, 2020 10 09.
Article in English | MEDLINE | ID: mdl-33033216

ABSTRACT

Linking genomic variation to phenotypical traits remains a major challenge in evolutionary genetics. In this study, we use phylogenomic strategies to investigate a distinctive trait among mammals: the development of masculinizing ovotestes in female moles. By combining a chromosome-scale genome assembly of the Iberian mole, Talpa occidentalis, with transcriptomic, epigenetic, and chromatin interaction datasets, we identify rearrangements altering the regulatory landscape of genes with distinct gonadal expression patterns. These include a tandem triplication involving CYP17A1, a gene controlling androgen synthesis, and an intrachromosomal inversion involving the pro-testicular growth factor gene FGF9, which is heterochronically expressed in mole ovotestes. Transgenic mice with a knock-in mole CYP17A1 enhancer or overexpressing FGF9 showed phenotypes recapitulating mole sexual features. Our results highlight how integrative genomic approaches can reveal the phenotypic impact of noncoding sequence changes.


Subject(s)
Adaptation, Physiological/genetics , Fibroblast Growth Factor 9/genetics , Moles/genetics , Regulatory Elements, Transcriptional , Sex Differentiation/genetics , Steroid 17-alpha-Hydroxylase/genetics , Animals , Chromosome Inversion , Datasets as Topic , Female , Gene Expression Regulation , Genome , Mice , Mice, Transgenic , Tandem Repeat Sequences , Testosterone/blood , Testosterone/genetics
14.
PLoS One ; 15(9): e0239231, 2020.
Article in English | MEDLINE | ID: mdl-32997686

ABSTRACT

It is controversially discussed whether immune-deficient mice experience severity in the absence of infection. Because a comprehensive analysis of the well-being of immune-deficient mice under specific pathogen free conditions is missing, we used a multi-parametric test analyzing, corticosterone, weight, nest building and facial expression over a period of 9 month to determine the well-being of two immune-deficient mouse lines (recombination activating gene 2- and interferon gamma receptor-deficient mice). We do not find evidence for severity when comparing immune-deficient mice to their heterozygous immune-competent littermates. Our data challenge the assumption that immune-deficiency per se regardless of housing conditions causes severity. Based on our study we propose to use objective non-invasive parameters determined by laboratory animal science for decisions concerning severity of immune-deficient mice.


Subject(s)
Corticosterone/genetics , DNA-Binding Proteins/genetics , Interferon-gamma/genetics , Mice, SCID/genetics , Animals , B-Lymphocytes/immunology , Corticosterone/immunology , Humans , Infections/genetics , Infections/immunology , Kidney/metabolism , Kidney/pathology , Mice , Mice, SCID/immunology , Pain/genetics , Pain/pathology , Receptors, Interferon/deficiency , Receptors, Interferon/genetics , Signal Transduction/genetics , T-Lymphocytes/immunology , Testosterone/genetics , Interferon gamma Receptor
15.
Genes (Basel) ; 11(7)2020 06 29.
Article in English | MEDLINE | ID: mdl-32610558

ABSTRACT

Testosterone has historically been linked to sexual dysfunction; however, it has recently been shown to affect other physical and mental attributes. We attempted to determine whether changes in serum testosterone could play a role in chronic or degenerative diseases. We used two separate genetic instruments comprising of variants from JMJD1C and SHBG regions and conducted a two-sample Mendelian randomization for type II diabetes (T2D), gout, rheumatoid arthritis (RA), schizophrenia, bipolar disorder, Alzheimer's disease and depression. For the JMJD1C locus, one unit increase in log transformed testosterone was significantly associated with RA (OR = 1.69, p = 0.02), gout (OR = 0.469, p = 0.001) and T2D (OR = 0.769, p = 0.048). Similarly, one unit increase in log transformed testosterone using variants from the SHBG locus was associated with depression (OR = 1.02, p < 0.0001), RA (OR = 1.254, p < 0.0001) and T2D (OR = 0.88, p < 0.0001). Our results show that low levels of serum testosterone levels may cause gout and T2D, while higher than normal levels of testosterone may result in RA and depression. Our findings suggest that fluctuations in testosterone levels may have severe consequences that warrant further investigation.


Subject(s)
Alzheimer Disease/genetics , Arthritis/genetics , Depression/genetics , Diabetes Mellitus, Type 2/genetics , Polymorphism, Single Nucleotide , Schizophrenia/genetics , Testosterone/blood , Alzheimer Disease/blood , Arthritis/blood , Depression/blood , Diabetes Mellitus, Type 2/blood , Humans , Jumonji Domain-Containing Histone Demethylases/genetics , Male , Mendelian Randomization Analysis , Oxidoreductases, N-Demethylating/genetics , Schizophrenia/blood , Sex Hormone-Binding Globulin/genetics , Testosterone/genetics
16.
Sci Rep ; 10(1): 10479, 2020 06 26.
Article in English | MEDLINE | ID: mdl-32591571

ABSTRACT

Polycystic ovary syndrome (PCOS) is a highly complex disorder influenced by genetic and environmental factors. Previous genome-wide association studies (GWAS) on Han Chinese, Korean, and European populations identified multiple PCOS-susceptible loci; however, only a few studies reported the association of susceptibility genes with disease phenotypic traits. This cross-sectional study aimed to investigate the association between PCOS susceptibility genes from GWAS and disease-related clinical features. A total of 1,810 reproductive-aged women were recruited, including 927 control women and 883 women with PCOS, diagnosed based on the European Society for Human Reproduction and Embryology criteria. Genomic DNA was extracted and genotyped, and a Bonferroni test was performed to determine the association between 12 independent SNPs and the clinical features of PCOS. In women with PCOS, rs11031006, nearest to FSHB, was significantly associated with free testosterone (P = 1.94 × 10-3) and luteinizing hormone (P = 1.96 × 10-3) levels. The menstruation number per year, ovarian follicular number, ovarian volume, and insulin sensitivity index were not associated with any SNP. In the control group, no SNPs were associated with any PCOS traits. Collectively, our results suggest that FSHB may play an important role in the development and progression of PCOS.


Subject(s)
Genetic Predisposition to Disease/genetics , Polycystic Ovary Syndrome/genetics , Polymorphism, Single Nucleotide/genetics , Adult , Asian People/genetics , Case-Control Studies , Cross-Sectional Studies , Female , Gene Frequency/genetics , Genome-Wide Association Study/methods , Genotype , Humans , Insulin Resistance/genetics , Luteinizing Hormone/genetics , Male , Phenotype , Testosterone/genetics , Young Adult
17.
Respirology ; 25(12): 1265-1273, 2020 12.
Article in English | MEDLINE | ID: mdl-32583532

ABSTRACT

BACKGROUND AND OBJECTIVE: IPF is an ageing-related lung disorder featuring progressive lung scarring. IPF patients are frequently identified with short telomeres but coding mutations in telomerase can only explain a minority of cases. Sex hormones regulate telomerase activity in vitro and levels of sex hormones are related to LTL. The objective of this study was to explore whether sex hormones were associated with LTL, whether they interacted with genetic variants in telomerase and whether polymorphisms in the exon of androgen metabolism genes were associated with plasma testosterone concentrations in male IPF patients. METHODS: A case-control study was performed on 101 male IPF subjects and 51 age-matched healthy controls. Early morning plasma sex hormones were quantified, and whole-exome sequencing was used to identify rare protein-altering variants of telomerase and SNP in the exon of androgen metabolism genes. LTL was analysed by PCR and expressed as a T/S ratio. RESULTS: LTL, testosterone and DHT were decreased significantly in the IPF group. After adjustments for age and variant status in telomerase-related genes, only testosterone was positively associated with LTL (P = 0.001). No significant interaction (P = 0.661) was observed between rare protein-altering variants of telomerase and testosterone. No coding SNP in androgen metabolism genes were significantly associated with testosterone concentrations. CONCLUSION: Plasma testosterone is associated with LTL independent of age or rare protein-altering variants of telomerase. No genetic variations of androgen-related pathway genes are associated with androgen concentrations. Further studies are warranted to examine whether hormonal interventions might retard telomere loss in male IPF patients.


Subject(s)
Aging/physiology , Androgens , Idiopathic Pulmonary Fibrosis , Leukocytes/physiology , Telomerase/genetics , Testosterone , Androgens/blood , Androgens/genetics , Androgens/metabolism , Case-Control Studies , Correlation of Data , Humans , Idiopathic Pulmonary Fibrosis/blood , Idiopathic Pulmonary Fibrosis/genetics , Idiopathic Pulmonary Fibrosis/metabolism , Male , Middle Aged , Mutation , Telomere Shortening/physiology , Testosterone/blood , Testosterone/genetics , Exome Sequencing/methods
18.
Reprod Fertil Dev ; 32(10): 885-892, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32586418

ABSTRACT

High temperature can reduce testes function, leading to decreased testosterone secretion. Dietary l-arginine (l-Arg) supplementation improves the semen quality and libido of boars. The present study investigated whether l-Arg could enhance the production of testosterone in mice exposed to high ambient temperature. Twenty-four 6-week-old male ICR mice were randomly divided into three groups: a control group, a heat-treated (HT) group and a group subjected to heat treatment plus 2mg kg-1 l-Arg (HT+Arg). l-Arg was administered to mice by oral gavage for 18 consecutive days, after which the HT and HT+Arg groups were placed into an incubator at 40°C for 30min every day for 5 days. Serum testosterone and LH concentrations were significantly increased in the HT+Arg compared with HT group, as was catalase, total superoxide dismutase and glutathione peroxidase activity and the expression of steroidogenesis-related genes steroidogenic acute regulatory protein (Star), steroidogenic factor-1 (Sf1), 17ß-hydroxysteroid dehydrogenase 3 (Hsd17b3) and 17α-hydroxylase/17,20-lyase (Cyp17a1) in the testes. These results demonstrate that l-Arg can alleviate testosterone reductions in heat-treated mice by upregulating LH secretion, enhancing the antioxidant system and increasing the expression of testosterone synthesis-related genes.


Subject(s)
Antioxidants/metabolism , Arginine/administration & dosage , Hot Temperature/adverse effects , Luteinizing Hormone/blood , Testis/metabolism , Testosterone/genetics , Animals , Catalase/blood , Cyclic AMP/analysis , Gene Expression/drug effects , Male , Mice , Mice, Inbred ICR , Nitric Oxide/analysis , Superoxide Dismutase/blood , Testis/chemistry , Testosterone/blood
19.
Article in English | MEDLINE | ID: mdl-32298809

ABSTRACT

The pejerrey is an atherinopsid species from South America that presents a combination of genotypic and environmental (temperature-dependent) sex determination whereby low and high temperatures induce feminization and masculinization, respectively. Masculinization involves a heat-induced stress response leading to increased circulating cortisol and androgens. We tested whether crowding would elicit a similar response as high temperature and affect the sex ratios of pejerrey. Larvae with XX and XY genotypes were reared at 15, 62 and 250 larvae/L in 0.4, 1.6, and 6.4 L containers during a period considered critical for sex determination at 25 °C, a mixed-sex promoting temperature. Fish were analysed at 3-7 weeks for whole-body cortisol and 11-ketotestosterone (11-KT) titer and hydroxy-steroid dehydrogenase (hsd11b2) mRNA transcript abundance, and after completion of gonadal sex differentiation (10-14 weeks) for determination of phenotypic and genotypic sex mismatches. Crowding was associated with depressed growth, higher cortisol and 11-KT titers, increased hsd11b2 transcription, and increased frequency of masculinization compared to intermediate and/or low rearing densities. Perceived crowding (by rearing in containers with mirror-finish, reflecting walls) also caused masculinization. These results suggest the possibility that other environmental factors besides temperature can also affect sex determination in pejerrey and that a stress response leading to increased cortisol and androgen levels, which is potentially perceived by the brain, may be a common feature among different forms of environmental sex determination in this species.


Subject(s)
Crowding , Fishes/physiology , Sex Determination Processes , Stress, Physiological , Temperature , Animals , Female , Fishes/genetics , Gene Expression Profiling , Humans , Hydrocortisone/analysis , Immunoenzyme Techniques , Male , Testosterone/analogs & derivatives , Testosterone/analysis , Testosterone/genetics
20.
J Hum Genet ; 65(8): 683-691, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32341457

ABSTRACT

Semen quality is affected by environmental factors, endocrine function abnormalities, and genetic factors. A GWAS recently identified ERBB4 at 2q34 as a genetic locus associated with sperm motility. However, GWASs for human semen volume and sperm concentration have not been conducted. In addition, testis size also reportedly correlates with semen quality, and it is important to identify genes that affect testis size. Reproductive hormones also play an important role in spermatogenesis. To date, genetic loci associated with plasma testosterone, sex hormone-binding globulin (SHBG), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels have been identified using GWASs. However, GWASs have not identified any relevant loci for plasma inhibin B levels. We conducted a two-stage GWAS using 811 Japanese men in a discovery stage followed by a replication stage using an additional 721 Japanese men. The results of the discovery and replication stages were combined into a meta-analysis. After setting a suggestive significance threshold for P values < 5 × 10-6 in the discovery stage, we identified ten regions with SNPs (semen volume: one, sperm concentration: three, testes size: two, and inhibin B: four). We selected only the most significant SNP in each region for replication genotyping. Combined discovery and replication results in the meta-analysis showed that the locus 12q21.31 associated with plasma inhibin B levels (rs11116724) had the most significant association (P = 5.7 × 10-8). The LRRIQ1 and TSPAN19 genes are located in the 12q21.31 region. This study provides new susceptibility variants that contribute to plasma inhibin B levels.


Subject(s)
Inhibins/blood , Semen/metabolism , Testis/growth & development , Testosterone/genetics , Adult , Asian People/genetics , Follicle Stimulating Hormone/genetics , Follicle Stimulating Hormone/metabolism , Genome-Wide Association Study , Humans , Luteinizing Hormone/blood , Luteinizing Hormone/genetics , Male , Organ Size , Polymorphism, Single Nucleotide , Semen Analysis , Sex Hormone-Binding Globulin/genetics , Sex Hormone-Binding Globulin/metabolism , Sperm Count , Testosterone/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...